Market Newsdesk

Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Medical Treatment Technology Co., Ltd. (“Hunan Saitumofei”) has entered into a one-year exclusive distribution agreement (the “Agreement”) with Shanghai Benke Medical Technology Co., Ltd. (“Shanghai Benke”) to promote and distribute its newly launched AI-Automated Blood Cell Morphology Analyzer (CM-B600) (the “Analyzer”) in East China throughout 2026. The collaboration is expected to accelerate market access and drive large-scale commercialization of the new product.

Pursuant to the Agreement, Hunan Saitumofei has granted Shanghai Benke exclusive distribution rights for the Analyzer in East China, covering Jiangsu Province, Shanghai Municipality, and Zhejiang Province — core markets within China’s economically dynamic Yangtze River Delta region — from January 1 to December 31, 2026. The Agreement establishes a minimum annual sales target of RMB 10 million (approximately US$1.4 million). Shanghai Benke has prepaid a performance bond of RMB 1 million, which will be deducted from the final payment or refunded without interest upon achievement of the sales target.

The Analyzer received manufacturing approval as a Class II medical device from a Chinese regulatory authority in November 2025 and is certified under applicable national and industry standards, including GB 4793.1 and YY 0648. Leveraging high-resolution digital imaging technology, the Analyzer simulates the gold-standard workflow of manual microscopic examination. Through region-based level set segmentation and Support Vector Machine (SVM) algorithms, it automatically completes sample scanning, identification, and classification.

Powered by advanced AI-driven automation, the Analyzer delivers high imaging speed and classification accuracy. It can process up to 150 samples per batch, with an additional emergency slot, achieving an average detection time of no more than three minutes per blood smear. The system delivers classification accuracy of no less than 90% for lymphocytes, neutrophils, eosinophils, basophils, and mature white blood cells per slide. In addition, it can identify 17 subtypes of white blood cells and provides detailed morphological analyses of red blood cells (including acanthocytes, target cells, and fragments) as well as platelet characteristics (such as size classification and aggregation identification). The Analyzer also supports a database capacity of more than 350,000 high-definition blood cell images.

Notably, the Analyzer employs non-deep-learning feature extraction algorithms such as nucleus-to-cytoplasm ratio and granularity analysis, offering high interpretability and substantially reducing potential clinical risks.

Mr. Shuang Wu, Chief Executive Officer and Chairman of the Board of Directors of WORK Medical, commented: “We are pleased to announce this agency agreement shortly after receiving manufacturing approval, which underscores both the commercial readiness of the Analyzer and the market’s recognition of our technology and brand. By leveraging Shanghai Benke’s established medical device sales network and deep roots in the East China market, we aim to accelerate market penetration of the Analyzer and further strengthen WORK Medical’s nationwide brand presence. We believe this rollout in East China will serve as a benchmark for broader adoption, laying a solid foundation for future expansion across China and into international markets.”

About WORK Medical Technology Group LTD

WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

For more information, please contact:

WORK Medical Technology Group LTD

Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]

IRVING, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) — XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a workflow automation leader that leverages decades of industry experience, a global footprint, and agentic AI to rethink business process automation and digital transformation, announced a strategic, multi-year partnership with a leading U.S. based property and casualty (P&C) insurance provider. The engagement, valued at approximately $24 million over five years, will modernize the insurer’s payment ecosystem through XBP’s intelligent, automation solutions.

As part of the partnership, XBP will deploy its advanced AI-driven and RPA-infused automation platform to digitize and streamline end-to-end payment operations specifically designed for the P&C insurance processing. A key component of this transformation is the implementation of XBP’s Mobile Payment solution, enabling secure, seamless, and compliant mobile transactions for policyholders while significantly enhancing speed and convenience.

Leveraging XBP’s Intelligent Document Processing (IDP) technology, the insurer will automate the capture, extraction, and validation of payment-related data, reducing manual intervention and accelerating reconciliation. XBP will also implement its Exception Platform and correspondence digitization capabilities to intelligently manage exceptions, improve accuracy, and ensure faster resolution across remittance and payment workflows.

The engagement will further convert paper-based correspondence into secure digital formats, improving operational efficiency, strengthening compliance, and reducing processing time. Together, these capabilities create a future-ready payments framework that blends AI, RPA, and mobile-first innovation to support scalability and evolving client expectations.

“We are proud to partner with a leading insurer to reimagine payment operations through our AI-driven, hyper-automation enabled ecosystem,” said Lakshmi Narayanan, President – Bills and Payments, XBP Americas. “This engagement highlights the growing demand for intelligent, mobile-enabled payment solutions that deliver efficiency, accuracy, and an improved customer experience at scale.”

This collaboration with XBP will enable the modernization of the client’s payments infrastructure through a secure, mobile-enabled, and automation-led approach that enhances efficiency while advancing compliance and customer experience goals.

Forward-Looking Statements


This press release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These statements include financial forecasts, projections, and other statements about future operations, financial position, business strategy, market opportunities, and trends. Forward-looking statements can often be identified by terms such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast,” or similar expressions. This press release includes forward-looking non-GAAP financial measures, such as projected Adjusted EBITDA and Net Debt. Adjusted EBITDA is defined as net income excluding interest, taxes, depreciation, amortization, and certain non-recurring items, while Net Debt is total debt minus cash and cash equivalents. The Company cannot reconcile these measures to their most comparable GAAP metrics — net income and total debt — without unreasonable effort, due to challenges in forecasting future interest, taxes, depreciation, and non-recurring items. These measures are provided for informational purposes only and should not be considered substitutes for financial measures prepared in accordance with GAAP. All forward-looking statements are based on estimates, forecasts, and assumptions that are inherently uncertain and subject to risks and factors that could cause actual results to differ materially. These include, but are not limited to: (1) risks related to the acquisition, including the inability to realize anticipated benefits, disruptions to operations, and costs associated with the transaction; (2) legal proceedings; (3) failure to meet Nasdaq listing standards; (4) competition and market conditions; (5) economic, geopolitical, and regulatory changes; (6) challenges in retaining clients, employees, and suppliers; and (7) other risks detailed in XBP Europe’s filings with the SEC, including the “Risk Factors” section of its Annual Report on Form 10-K for 2025, filed on March 19, 2025, and the proxy statement for the 2025 annual meeting. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. XBP Global undertakes no obligation to update these statements, except as required by law. There is no assurance that XBP Global or its subsidiaries will achieve the results projected in these statements.

About XBP Global

XBP Global is a multinational technology and services company powering intelligent workflows for organizations worldwide. With a presence in 20 countries and approximately 11,000 professionals, XBP Global partners with over 2,500 clients, including many of the Fortune 100, to orchestrate mission-critical systems that enable hyper-automation.

Our proprietary platforms, agentic AI-driven automation, and deep domain expertise across industries and the public and private sectors enable our clients to entrust us with their most impactful digital transformations and workflows. By combining innovation with execution excellence, XBP Global helps businesses reimagine how they work, transact, and unlock value.

For more news, commentary, and industry perspectives, visit: https://www.xbpglobal.com/

And please follow us on social:

X: https://X.com/XBPglobal

LinkedIn: https://www.linkedin.com/company/xbpglobal/

The information posted on XBP Global’s website and/or via its social media accounts may be deemed material to investors. Accordingly, investors, media and others interested in XBP Global should monitor XBP Global’s website and its social media accounts in addition to XBP Global’s press releases, SEC filings and public conference calls and webcasts.

Investor Relations: David Shamis, [email protected] | Media Queries: Srushti Rao, [email protected]

KISSIMMEE, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design, Inc. (“ECD” or the “Company”) (NASDAQ: ECDA), the world’s largest Land Rover and Jaguar restoration company known for its custom luxury builds, including bespoke Defenders, Range Rovers, Jaguar E-Types, Ford Mustangs, and Toyota FJs, today announced the launch of its Luxury Agent Program, a new sales channel designed to complement the Company’s existing direct-to-consumer strategy, expand market reach, and increase production.

Under the Luxury Agent Program, ECD will partner with select U.S.-based luxury and exotic automotive advisors, including dealers and professionals (the “Luxury Agents”) deeply embedded in the high-net-worth and collector vehicle ecosystem. These Luxury Agents will introduce qualified clients to ECD’s full portfolio of classic and modern 4x4s and its boutique lineup of Jaguar, Porsche, Mustang, and BMW builds. ECD’s in-house design team will then take over the customization process, leading clients through the high-touch, one-of-one experience for bespoke upgrades and hands-on project management through delivery.

“As we expand our product lineup and focus on increasing factory utilization, broadening our sales reach is a natural next step,” said Scott Wallace, CEO and Co-Founder of ECD. “The Luxury Agent Program enables us to partner with trusted advisors serving the luxury automobile market to drive incremental demand across our portfolio. The Program should improve production efficiency, and enhance fixed-cost absorption, all while building our brand and preserving the craftsmanship, design, and high-touch customer experience that sets ECD apart.”

Early market response to the program has been positive. ECD has onboarded and trained its first Luxury Agent, who will earn a commission on the base vehicle price for each successfully completed build. The Company expects to continue expanding the agent network throughout 2026.

The Luxury Agent Program builds on ECD’s December 26, 2025 increased product offering announcement, which outlined expanded heritage and modern vehicle platforms, enhanced engineering capabilities, and a renewed focus on operational efficiency and factory utilization heading into 2026.

About ECD Auto Design

ECD, a public company trading under ECDA on the Nasdaq, is a creator of restored luxury vehicles that combines classic English beauty with modern performance. Currently, ECD restores Land Rover Defenders, Land Rover Series IIA, the Range Rover Classic, the Jaguar E-Type and we have recently added Ford Mustang and Toyota FJ. Historically, each vehicle produced by ECD was fully bespoke, a one-off that is designed by the client through an immersive luxury design experience and hand-built from the ground up in 2,200 hours by master-certified Automotive Service Excellence (“ASE”) craftsmen. The Company was founded in 2013 by three British “gear heads’ whose passion for classic vehicles is the driving force behind exceptionally high standards for quality, custom luxury vehicles. ECD’s global headquarters, known as the “Rover Dome,” is a 100,000-square-foot facility located in Kissimmee, Florida that is home to 98 staff with 67 talented craftsmen and technicians, who hold a combined 66 ASE and three master level certifications. ECD has an affiliated logistics center in the U.K. where its employees work to source and transport 25-year-old work vehicles back to the U.S. for restoration. For more information, visit www.ecdautodesign.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “attempting,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. You should carefully consider the risks and uncertainties that affect our business, including those described in our filings with the Securities and Exchange Commission (“SEC”), including under the caption “Risk Factors” in our Annual Report on Form 10-K filed for the year ended December 31, 2024 with the SEC, which can be obtained on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this communication. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements, whether as a result of any new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our public announcements and filings with the SEC.

Investor Relations

[email protected]

RANCHO CUCAMONGA, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) — iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”) today announced that it has completed its initial acquisitions under its Digital Asset Treasury (“DAT”) strategy, marking the Company’s first deployment of capital into digital assets.

On Friday, December 26, 2025, through a subsidiary account maintained at BitGo, iPower executed the following transactions as part of its DAT strategy:

• Purchased 15.1 Bitcoin (BTC) at an average price of $87,686.33 per BTC, for a total notional value of approximately $1,325,400; and
• Purchased 301.1 Ethereum (ETH) at an average price of $2,934.67 per ETH, for a total notional value of approximately $883,600.

“We view this initial deployment as an important milestone in executing our broader crypto strategy,” said Lawrence Tan, CEO of iPower. “These purchases reflect a disciplined and measured approach to building digital asset exposure, supported by defined custody and control arrangements. We intend to continue evaluating additional purchases over time, subject to market conditions and our internal risk management framework.”

iPower noted that it may make additional digital asset purchases in the coming weeks, depending on market conditions and capital availability, consistent with the parameters of its DAT strategy.

About iPower Inc.

iPower Inc. (Nasdaq: IPW) is a technology- and data-driven online retailer and a provider of value-added e-commerce services for third-party products and brands. iPower operates a nationwide fulfillment network and is expanding infrastructure across software, logistics, and manufacturing, with an aim to also pursue initiatives in digital assets and blockchain integration. For more information, please visit www.meetipower.com.

Forward-Looking Statements

All statements other than statements of historical fact in this press release are forward-looking statements, including statements regarding the implementation of iPower’s DAT strategy, the anticipated benefits of holding digital assets, and iPower’s future business plans in this sector. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that iPower believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. iPower undertakes no obligation to update forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as may be required by law. Although iPower believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and iPower cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results and performance in iPower’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other SEC filings.

Media & Investor Contact

[email protected]

• Mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditions
• Supported by Health Moonshot Champions, including the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates Ventures
• Apollo House, the Founders & Funders Networking Summit, to bring together founders, funders and industry leaders addressing Health Moonshots worldwide
• Longeveron will also be hosting meetings with institutional investors and potential partners during the week

MIAMI, Dec. 29, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that, as a StartUp HealthAlzheimer’s & Brain Health Moonshot company, it will be participating in StartUp Health Apollo House during JPM Healthcare Week in January 2026.

StartUp Health Alzheimer’s & Brain Moonshot is a mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditions, supported by Health Moonshot Champions, including the Alzheimer’s Drug Discovery Foundation (ADDF) and Gates Ventures. Apollo House, the Founders & Funders Networking Summit, is intended to bring together founders, funders and industry leaders addressing Health Moonshots worldwide.

Longeveron will also be hosting meetings with institutional investors and potential partners during JPM Healthcare Week. Please contact [email protected] to schedule a meeting with members of Longeveron’s senior management.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B^®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Forward-Looking Statements

Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Contact:

Derek Cole
Investor Relations Advisory Solutions
[email protected]

IRVINE, CA., Dec. 29, 2025 (GLOBE NEWSWIRE) — Clean Energy Technologies, Inc. (Nasdaq: CETY) (“CETY” or the “Company”), a clean energy technology company delivering scalable solutions in power generation, storage, waste-to-energy, and heat-to-power, today announced that Vermont Renewable Gas, LLC (“VRG”), a CETY affiliate, has submitted its first round of discovery responses in the Vermont Public Utility Commission’s Certificate of Public Good (CPG) review process for its proposed 2.2 MW renewable electric generation facility in Lyndon, Vermont.

The submission represents a routine and collaborative step in Vermont’s established regulatory framework and reflects continued engagement with state agencies involved in the review process, including the Vermont Public Utility Commission, the Agency of Natural Resources, the Department of Public Service, and the Agency of Agriculture, Food and Markets.

The CPG process is designed to provide a transparent and comprehensive evaluation of renewable energy projects to ensure consistency with public interest objectives, including environmental stewardship, public health and safety, and responsible resource management. VRG continues to advance the project in coordination with regulators and community stakeholders as the process moves forward toward subsequent development milestones, including progression toward Notice to Proceed (NTP) following completion of required approvals.

For further information, the CPG review docket for VRG can be accessed at https://epuc.vermont.gov/?q=node/64/200725/FV-Case%20Summary-Portal.

About Clean Energy Technologies, Inc. (CETY)

Headquartered in Irvine, California, Clean Energy Technologies, Inc. (CETY) is a rising leader in the zero-emission revolution by offering eco-friendly green energy solutions, clean energy fuels and alternative electric power for small and mid-sized projects in North America, Europe, and Asia. CETY also holds a minority ownership interest in, and is affiliated with Vermont renewable Gas LLC. We deliver power from heat and biomass with zero emission and low cost. The Company’s principal products are Waste Heat Recovery Solutions using our patented Clean CycleTM generator to create electricity. Waste to Energy Solutions convert waste products created in manufacturing, agriculture, wastewater treatment plants and other industries to electricity and BioChar. Engineering, Consulting and Project Management Solutions provide expertise and experience in developing clean energy projects for municipal and industrial customers and Engineering, Procurement and Construction (EPC) companies.

CETY’s common stock is currently traded on the Nasdaq Capital Market under the symbol “CETY.” For more information, visit www.cetyinc.com.

Follow CETY on our social media channels: Twitter | LinkedIn | Facebook

This summary should be read in conjunction with the Company’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2025 and other periodic filings made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, which contain, among other matters, risk factors and financial footnotes as well as a discussions of our business, operations and financial matters located on the website of the Securities and Exchange Commission at www.sec.gov.

Safe Harbor Statement

This news release may include forward-looking statements within the meaning of section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the Company’s analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the “Safe Harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations and assumptions regarding the future of CETY’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements can be identified by words such as: “anticipate,” “plan,” “expect,” “estimate,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Any forward-looking statement made by the Company in this press release is based only on information currently available to us and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Clean Energy Technologies, Inc.

Investor and Investment Media inquiries:
949-273-4990
[email protected]
Source: Clean Energy Technologies, Inc.

New York, NY, Dec. 29, 2025 (GLOBE NEWSWIRE) — Mixed Martial Arts Group (NYSE: MMA) (“MMA” or “the Company”), operating as MMA.INC, today announced that it has entered into definitive securities purchase agreements dated December 29, 2025 with accredited investors for the issuance and sale of 4,285,714 shares of Series A Preferred Stock (the “Preferred Stock”) of the Company at a price of $0.70 per share with a conversion price of $0.70 per share, on a brokered private placement basis, for aggregate gross proceeds of approximately $3 million, before deducting fees and offering expenses. In addition, the Company issued placement agent warrants (the “Placement Agent Warrants”) to purchase 342,857 ordinary shares at an exercise price of $0.70 per share.

The offering was led by American Ventures LLC with Donald Trump Jr investing in the offering, with Dominari Securities LLC acting as the exclusive placement agent for the Offering. The private placement is expected to close on December 30, 2025, subject to customary closing conditions.

The Company intends to use the proceeds from the offering to advance the Company’s platform expansion and build on recent momentum across its Web3 ecosystem strategy, fully activating its partnership with UFC GYM, capitalizing on the rapid growth of its gym software platform, BJJLink and adoption of its platform across the global community of fighters, gyms and fans.

In connection with the private placement, the Company and American Ventures LLC, Series XL MMA ELOC (“American Ventures”) entered into an Equity Purchase Agreement pursuant to which American Ventures agreed to purchase from the Company up to $20 million of ordinary shares from time to time subject to certain restrictions. In addition, the Company entered into a registration rights agreement with American Ventures to register up to $20 million of ordinary shares.

The securities offered and sold by the Company in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares underlying the Series A Preferred Stock and Placement Agent Warrants to be issued in the private placement. Any resale of the Company’s shares under such resale registration statement will be made only by means of a prospectus.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities will not be registered under the Securities Act or any state securities laws when issued at the closing of the private placement, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws.

About Mixed Martial Arts Group Limited

With over 5 million social media followers, 530,000 user profiles, 75,000+ active students, 18,000 published gyms and 800 verified gyms across 16 countries across its various assets, MMA.inc continues to transform the martial arts landscape and deliver unparalleled value to its stakeholders.

We are bringing together martial arts fans, fighters, gyms, and coaches in a single on chain ecosystem. Unlike other models that focus on digital collectibles or limited fan tokens, we’re all about real participation and achievement.

• From the Ground Up to Worldwide: With over 800 verified gyms, 75,000+ active students already training across 16 countries, MMA.INC connects local gyms with global communities in a single, connected network of value.
• Participation as Currency: Engaging in training, streaming, coaching or simply supporting any activity, will earn Experience Points (XP), which is transparently logged on chain and can be redeemed for real rewards.
• Merit over Speculation: Rewards will be based on effort, passion and progress, allowing the economy to grow through genuine participation rather than financial gain.
• One Unified Ecosystem: With existing platform assets including BJJLink, TrainAlta, Hype and MixedMartialArts.com, MMA.INC provides a complete platform that covers training, community, content and fandom like no other.

For more information, visit www.mma.inc 

Forward-Looking Statements

This press release contains forward-looking statements. Any statements contained herein regarding our strategy, potential digital asset treasury, potential MMA.INC token, platform development, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management, other than statements of historical facts, are forward-looking statements. The forward-looking statements included herein include or may include, but are not limited to, statements that are predictive in nature, depend upon or refer to future events or conditions, or use or contain words, terms, phrases, or expressions such as “achieve,” “forecast,” “plan,” “propose,” “strategy,” “envision,” “hope,” “will,” “continue,” “potential,” “expect,” “believe,” “anticipate,” “project,” “estimate,” “predict,” “intend,” “should,” “could,” “may,” “might,” or similar words, terms, phrases, or expressions or the negative of any of these terms. Any statements contained in this press release that are not based upon historical fact are based on current expectations, estimates, projections, opinions and/or beliefs of the Company. Such statements are not facts and involve known and unknown risks, uncertainties, and other factors. Prospective investors should not rely on these statements as if they were facts. Actual revenue may vary to current sales due to factors such as participant churn, cancellations, and changes in payment schedules, membership terms or pricing changes. Any references to verified gyms, partner gyms, user profiles refer to a database profile that has been claimed or created across the MMA.inc platform, which includes TrainAlta.com, BJJ Link, Hype, MixedMartialArts.com and Steppen. Forward-looking statements involve a number of known and unknown risks and uncertainties, including, but not limited to, those discussed in the “Risk Factors” section of the Form 20-F for the fiscal year ended June 30, 2025 filed with the SEC. Given the risks and uncertainties, readers should not place undue reliance on any forward-looking statement and should recognize that the statements are predictions of future results which may not occur as anticipated. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should carefully read the factors described in the “Risk Factors” section of the Form 20-F for the fiscal year ended June 30, 2025 filed with the SEC to better understand the risks and uncertainties inherent in our business and industry, and any underlying forward-looking statements. Except where required by law, the Company assumes no obligation to update, withdraw or revise any forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements.

Media Contacts

E: [email protected]